No results for ‘’
Aspira Pathlab & Diagnostics Ltd
₹131.25
(4.74%)
Fri, 02 Oct 2026, 07:15 pm
Health Services
Medical/Nursing Services
24.5KAspira Pathlab & Diagnostics Debt to Equity Ratio
| Particulars | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 19.65 | 14.96 | 0 | 0 | 43.37 |
| Price to book ratio | 0 | 26.34 | 85.65 | 0 | 8.67 | 5.22 | 2.25 | 3.15 | 7.21 |
| Price to sales ratio | 0 | 2.02 | 2.50 | 3.90 | 1.78 | 3.41 | 1.98 | 2.42 | 3.99 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 5.44 | 38.05 | 228.78 | 24.79 | 43.33 |
| Enterprise value | 0 | 19.95Cr | 31.55Cr | 45.54Cr | 32.96Cr | 68.98Cr | 29.63Cr | 33.31Cr | 88.78Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 9.38 | 10.82 | 18.60 | 0 | 24.96 |
| Debt to equity ratio | 1.23 | 33.92 | 1.46 | 2.34 | 0.25 | 0.31 | 0.26 | 0.27 | 0.26 |
| Return on equity % | 0 | -179.71 | -187.57 | -94.32 | 22.80 | 42.26 | -0.69 | -23.34 | 18.13 |
Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio
The Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio is a key financial metric used by investors to evaluate Aspira Pathlab & Diagnostics Ltd's valuation, profitability, and overall financial performance. Tracking the Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Aspira Pathlab & Diagnostics Ltd (NSE: , BSE: 540788) is currently trading at ₹131.25, with a market capitalization of ₹135.1Cr. As a leading company in the Health services sector and Medical/Nursing services industry, monitoring the Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio is essential for fundamental analysis.
Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio Current Value
The current Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio stands at 0.26.
The Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio Historical Trend
The Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio has shown the following historical trend:
- 2024: 0.26
- 2023: 0.27
- 2022: 0.26
- 2021: 0.31
- 2020: 0.25
The decline in Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio indicates improving financial efficiency or better earnings growth.
What Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio Indicates for Investors
The Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio plays a crucial role in understanding the company's financial health and valuation.
The D/E ratio measures financial leverage and balance sheet strength.
Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio Analysis Summary
The Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Aspira Pathlab & Diagnostics Ltd Debt to Equity Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.